Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes

Maturitas

Volumn 57, Issue 1, 2007, Pages 50-55

  Sismondi, Piero ^a   Biglia, Nicoletta ^a   Ponzone, Riccardo ^a   Fuso, Luca ^a   Scafoglio, Claudio ^b   Cicatiello, Luigi ^b   Ravo, Maria ^b   Weisz, Alessandro ^b   Cimino, Daniela ^a   Altobelli, Gioia ^a   Friard, Olivier ^a   De Bortoli, Michele ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Antagonists; Estrogen; Human therapy

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTICLE; BIOINFORMATICS; BREAST CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; DNA MICROARRAY; DOWN REGULATION; DRUG ANTAGONISM; DRUG MECHANISM; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENOMICS; HORMONAL REGULATION; HORMONE ACTION; HORMONE RESPONSE; HUMAN; REGULATORY SEQUENCE; TRANSCRIPTION REGULATION; UPREGULATION;

BREAST NEOPLASMS; CARCINOMA; DOWN-REGULATION; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 34247115465     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2007.02.019     Document Type: Article

References (25)

1. Katzenellenbogen B.S., Choi I., Delage-mourroux R., Ediger T.R., Martini P.G.V., Montano M., Sun J., Weis K., and Katzenellenbogen J.A. Molecular mechanisms of estrogen action: selective ligands receptor pharmacology. J Steroid Biochem Mol Biol 74 (2000) 279-285
2. Osborne C.K., Wakeling A., and Nicholson R.I. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90 Suppl 1 (2004) S2-S6
3. Stroheker T., Picard K., Lhuguenot J.C., Canivenc-Lavier M.C., and Chagnon M.C. Steroid activities comparison of natural and food wrap compounds in human breast cancer cell lines. Food Chem Toxicol 42 6 (2004) 887-897
4. Nilsson S., Makela S., Treuter E., et al. Mechanisms of estrogen action. Physiol Rev 81 4 (2001) 1535-1565
5. McDonnell D.P., and Norris J.D. Connections and regulation of the human estrogen receptor. Science 296 5573 (2002) 1642-1644
6. Sanchez R., Nguyen D., Rocha W., White J.H., and Mader S. Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays 24 (2002) 244-254
7. Coleman K.M., and Smith C.L. Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. Front Biosci 6 (2001) D1379-D1391
8. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., and Prossnitz E.R. A transmembrane intracellular receptor mediates rapid cell signaling. Science 307 (2005) 1625-1630
9. Perissi V., Staszewski L.M., McInerney E.M., et al. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev 13 24 (1999) 3198-3208
10. Perissi V., and Rosenfeld M.G. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 6 7 (2005) 542-554 [Review]
11. Glass C.K., and Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14 2 (2000) 121-141
12. Privalsky M.L. The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol 66 (2004) 315-360 [Review]
13. Klinge C.M. Estrogen receptor interaction with co-activators and co-repressors. Steroids 65 (2000) 227-251
14. Smith C.L., and O'Malley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25 1 (2004) 45-71
15. Cicatiello L., Scafoglio C., Altucci L., et al. A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol 32 3 (2004) 719-775
16. Weisz A., Basile W., Scafoglio C., et al. Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. J Cell Physiol 200 3 (2004) 440-450
17. Scafoglio C., Ambrosino C., Cicatiello L., et al. Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem 98 5 (2006) 1163-1184
18. Frasor J., Danes J.M., Komm B., Chang K.C., Lyttle C.R., and Katzenellenbogen B.S. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 10 (2003) 4562-4574
19. Frasor J., Stossi F., Danes J.M., Komm B., Lyttle C.R., and Katzenellenbogen B.S. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64 4 (2004) 1522-1533
20. Schiff R., Massarweh S.A., Shou J., et al. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56 Suppl 1 (2005) 10-20 [Review]
21. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., and Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 96 (2004) 926-935
22. Carlomagno C., Perrone F., Gallo C., et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14 (1996) 2702-2708
23. Ponzone R., Montemurro F., Maggiorotto F., et al. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. Ann Oncol 17 (2006) 1631-2163
24. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
25. Dowsett M., Cuzick J., Wale C., Howell T., Houghton J., and Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23 (2005) 7512-7517